Grace Therapeutics
GRCE
13 hedge funds and large institutions have $2.92M invested in Grace Therapeutics in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 3 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
14% more capital invested
Capital invested by funds: $2.55M → $2.92M (+$362K)
0% more ownership
Funds ownership: 0.07% → 0.07% (+0%)
7% less funds holding
Funds holding: 14 → 13 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
+$114K |
| 2 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$18.3K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$11.5K |
| 4 |
Morgan Stanley
New York
|
+$7.12K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$4.57K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$63K |
| 2 |
Renaissance Technologies
New York
|
-$25K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$16.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$12.6K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PA
1
Perceptive Advisors
New York
| $2.03M | – | – | – |
|
|
PVI
2
Pura Vida Investments
New York
| $380K | +$114K | +2,605 | +60% |
|
|
3
Bank of Montreal
Toronto,
Ontario, Canada
| $289K | +$4.57K | +104 | +2% |
|
|
4
Geode Capital Management
Boston,
Massachusetts
| $68K | +$11.5K | +262 | +26% |
|
|
5
Morgan Stanley
New York
| $52K | +$7.12K | +162 | +21% |
|
|
FDCDDQ
6
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $45.6K | +$3.47K | +79 | +10% |
|
|
PAG
7
Private Advisor Group
Morristown,
New Jersey
| $23K | +$18.3K | +417 | New |
|
|
8
UBS Group
Zurich,
Switzerland
| $15K | -$12.6K | -287 | -52% |
|
|
9
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $7K | -$16.7K | -380 | -75% |
|
|
10
Royal Bank of Canada
Toronto,
Ontario, Canada
| $5K | -$4K | -91 | -51% |
|
|
TC
11
Truvestments Capital
Sarasota,
Florida
| $1K | – | – | – |
|
12
Wells Fargo
San Francisco,
California
| $1K | +$922 | +21 | New |
|
|
RE
13
RBC Europe
London,
United Kingdom
| $34 | – | – | – |
|
|
CH
14
CVI Holdings
Wilmington,
Delaware
| – | -$63K | -1,281 | Closed |
|
|
15
Renaissance Technologies
New York
| – | -$25K | -510 | Closed |
|
GRCE Hedge Fund Activity: Q2 2019 in Review
13 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q2 2019, worth a combined $2.92M — up 14% from $2.55M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of GRCE and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 5 added.
The largest buyer was Pura Vida Investments, adding an estimated $114K. The largest seller was CVI Holdings, exiting entirely with an estimated $63K sold.
- 13 institutional investors held Grace Therapeutics (GRCE) as of Q2 2019, down from 14 in Q1 2019.
- Funds reported $2.92M of Grace Therapeutics stock for Q2 2019, up 14% quarter-over-quarter.
- 2 funds opened new Grace Therapeutics positions in Q2 2019 and 3 closed out, a net change of -1 holder.
- The largest Grace Therapeutics buyer in Q2 2019 was Pura Vida Investments, an estimated $114K added.
- The largest Grace Therapeutics seller in Q2 2019 was CVI Holdings, an estimated $63K sold.
Based on aggregated 13F filings for Q2 2019.